Differential response to exercise in claudin-low breast cancer Journal Article


Authors: Glass, O. K.; Bowie, M.; Fuller, J.; Darr, D.; Usary, J.; Boss, K.; Choudhury, K. R.; Liu, X.; Zhang, Z.; Locasale, J. W.; Williams, C.; Dewhirst, M. W.; Jones, L. W.; Seewaldt, V.
Article Title: Differential response to exercise in claudin-low breast cancer
Abstract: Exposure to exercise following a breast cancer diagnosis is associated with reductions in the risk of recurrence. However, it is not known whether breast cancers within the same molecular-intrinsic subtype respond differently to exercise. Syngeneic mouse models of claudin-low breast cancer (i.e., EO771, 4TO7, and C3(1)SV40Tagp16- luc) were allocated to a uniform endurance exercise treatment dose (forced treadmill exercise) or sham-exercise (stationary treadmill). Compared to shamcontrols, endurance exercise treatment differentially affected tumor growth rate: 1- slowed (EO771), 2- accelerated (C3(1)SV40Tag-p16-luc), or 3- was not affected (4TO7). Differential sensitivity of the three tumor lines to exercise was paralleled by effects on intratumoral Ki-67, Hif1-a, and metabolic programming. Inhibition of Hif1-α synthesis by the cardiac glycoside, digoxin, completely abrogated exerciseaccelerated tumor growth in C3(1)SV40Tag-p16-luc. These results suggest that intratumoral Hif1-α expression is an important determinant of claudin-low breast cancer adaptation to exercise treatment. © Glass et al.
Keywords: controlled study; protein expression; cancer growth; nonhuman; ki 67 antigen; cell proliferation; animal cell; mouse; animal tissue; breast cancer; animal experiment; animal model; exercise; digoxin; hypoxia inducible factor 1alpha; treadmill exercise; protein cleavage; growth rate; mouse model; claudin-low; claudin; female; article; breast cancer molecular subtype; hif1-a; endurance training
Journal Title: Oncotarget
Volume: 8
Issue: 60
ISSN: 1949-2553
Publisher: Impact Journals  
Date Published: 2017-11-24
Start Page: 100989
End Page: 101004
Language: English
DOI: 10.18632/oncotarget.21054
PROVIDER: scopus
PMCID: PMC5731850
PUBMED: 29254140
DOI/URL:
Notes: Article -- Export Date: 2 January 2018 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Lee Winston Jones
    176 Jones